AdipoSeeds announced an equity financing on 16 October 2026 involving Toho Holdings and Kohjin Bio. The amount and lead investor were not stated. The Tokyo company develops platelet based regenerative products and services supporting platelet rich plasma treatments. Founded in July 2016 around research by Keio University's Yumiko Matsubara and colleagues, it is developing platelet like cells derived from human adipose tissue. Proceeds will support preparations for Japanese clinical development and expansion of its plasma processing business. The strategic relationships also cover potential distribution infrastructure and manufacturing support. The announcement describes development plans, not regulatory approval or proven therapeutic efficacy.
AdipoSeeds secures strategic backing for platelet therapies
Toho Holdings and Kohjin Bio invest in the Tokyo biotechnology company

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


